Johnson & Johnson : Results from Phase 2 THOR-2 Study Show I

News Release


Media Contacts:


Suzanne Frost


+1 416-317-0304


Brian Kenney +1 215-620-0111

...

Related Keywords

United Kingdom , Madrid , Spain , James Wf Catto , Indianj Urol , Clin Urol , Obrian Kenney , Kiran Patel , Jnjinnovmedand Janssen , Exchange Commission , Drug Administration , Johnson , Clinical Development , Companies Of Johnson , European Society For Medical Oncology , Department Of Oncology , European Society For Medical Oncology Congress , None Of Janssen Research Development , Janssen Research Development , Astex Pharmaceuticals , Us Food Drug Administration , University Of Sheffield , Janssen Biotech Inc , Janssen Pharmaceutical Companies Of Johnson , News Release , Show Improved Rates , Recurrence Free Survival , High Risknon Muscle Invasive Bladder Cancer , Janssen Pharmaceutical Companies , Bacillus Calmette Gu , Proffered Paper , European Society , Medical Oncology , Hazard Ratio , Confidence Interval , Vice President , Solid Tumors , Janssen Research , Supplemental New Drug Application , European Medicines Agency , Janssen Pharmaceutica , Soft Tissue Mineralization , Specific Populations , Prescribing Informationfor , Pharmaceutical Companies , Pulmonary Hypertension , Janssen Biotech , Private Securities Litigation Reform Act , Annual Report , Note Regarding Forward Looking , Quarterly Reports , With High Risknon Muscle Invasive Bladder Cancer , Who Received Prior Bacillus Calmette Gu , Participants With Advanced Solid Tumors , Fibroblast Growth Factor Receptor , Accessed May , Unresponsivenon Muscle Invasive Bladder Cancer , Current Treatment Landscape , Novel Emerging Molecular , Intj Mol , Markets ,